Vertex's Orkambi points to more effective CF therapies
This article was originally published in Scrip
Executive Summary
The development of Vertex's fixed-dose combination for cystic fibrosis Orkambi (ivacaftor plus lumacaftor) should provide some benefit to patients with the most common mutation associated with the disease but really just paves the way for more effective treatments, experts say.